Catalent to Sell Somerset Oral Solids Facility to Ardena

On Oct 14, 2024

Catalent, Inc., a leader in enabling pharma, biotech, and consumer health companies to optimize product development, launch, and full life-cycle supply for patients around the world, has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset to Ardena, a contract development and manufacturing organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed.

The Somerset facility also houses Catalent’s corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new location. The new location of the corporate headquarters will be announced at a later date.

In recent years, Catalent has invested in oral solid capabilities at other facilities in the United States and Europe, expanding its commercial spray drying capabilities, oral high potent API handling capabilities, and manufacturing capacity across its network. Most notably, in October 2022, Catalent acquired its 333,000-square-foot Greenville, NC facility for $475 million. This state-of-the-art facility features fit-for-scale capacity with potent handling capabilities and specializes in turnkey solutions for oral solid dosage forms, including formulation development, analytical services, commercial manufacturing and packaging.

Catalent helps accelerate over 1,500 partner development programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply nearly 70 billion doses of nearly 8,000 products annually. Its workforce of approximately 17,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, the company generated approximately $4.4 billion in revenue in its 2024 fiscal year.

To access more business news, visit NJB News Now.

Related Articles: